Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Cash from Operations (2019 - 2025)

Harmony Biosciences Holdings' Cash from Operations history spans 7 years, with the latest figure at 126151000.0 for Q4 2025.

  • For Q4 2025, Cash from Operations rose 66.95% year-over-year to 126151000.0; the TTM value through Dec 2025 reached 348199000.0, up 58.4%, while the annual FY2025 figure was 348199000.0, 58.4% up from the prior year.
  • Cash from Operations for Q4 2025 was 126151000.0 at Harmony Biosciences Holdings, up from 108734000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 126151000.0 in Q4 2025 and bottomed at 12530000.0 in Q1 2021.
  • The 5-year median for Cash from Operations is 40046000.0 (2021), against an average of 51521500.0.
  • The largest annual shift saw Cash from Operations surged 273.97% in 2021 before it decreased 28.92% in 2022.
  • A 5-year view of Cash from Operations shows it stood at 37533000.0 in 2021, then fell by 28.92% to 26678000.0 in 2022, then surged by 187.37% to 76665000.0 in 2023, then dropped by 1.44% to 75562000.0 in 2024, then soared by 66.95% to 126151000.0 in 2025.
  • Per Business Quant, the three most recent readings for HRMY's Cash from Operations are 126151000.0 (Q4 2025), 108734000.0 (Q3 2025), and 79327000.0 (Q2 2025).